|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRD5A1 |
Gene summary for SRD5A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRD5A1 | Gene ID | 6715 |
| Gene name | steroid 5 alpha-reductase 1 | |
| Gene Alias | S5AR 1 | |
| Cytomap | 5p15.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P18405 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6715 | SRD5A1 | LZE4T | Human | Esophagus | ESCC | 2.23e-06 | 1.56e-01 | 0.0811 |
| 6715 | SRD5A1 | LZE22T | Human | Esophagus | ESCC | 7.00e-06 | 4.33e-01 | 0.068 |
| 6715 | SRD5A1 | LZE24T | Human | Esophagus | ESCC | 7.10e-05 | 2.25e-01 | 0.0596 |
| 6715 | SRD5A1 | P1T-E | Human | Esophagus | ESCC | 4.94e-13 | 9.69e-01 | 0.0875 |
| 6715 | SRD5A1 | P2T-E | Human | Esophagus | ESCC | 7.08e-17 | 5.08e-01 | 0.1177 |
| 6715 | SRD5A1 | P4T-E | Human | Esophagus | ESCC | 1.83e-15 | 4.34e-01 | 0.1323 |
| 6715 | SRD5A1 | P5T-E | Human | Esophagus | ESCC | 3.80e-08 | 3.43e-01 | 0.1327 |
| 6715 | SRD5A1 | P8T-E | Human | Esophagus | ESCC | 2.47e-13 | 2.14e-01 | 0.0889 |
| 6715 | SRD5A1 | P9T-E | Human | Esophagus | ESCC | 1.14e-07 | 9.67e-02 | 0.1131 |
| 6715 | SRD5A1 | P10T-E | Human | Esophagus | ESCC | 6.61e-17 | 3.04e-01 | 0.116 |
| 6715 | SRD5A1 | P11T-E | Human | Esophagus | ESCC | 1.67e-08 | 3.35e-01 | 0.1426 |
| 6715 | SRD5A1 | P12T-E | Human | Esophagus | ESCC | 3.31e-10 | 3.60e-01 | 0.1122 |
| 6715 | SRD5A1 | P15T-E | Human | Esophagus | ESCC | 2.28e-07 | 1.14e-01 | 0.1149 |
| 6715 | SRD5A1 | P16T-E | Human | Esophagus | ESCC | 3.87e-16 | 2.60e-01 | 0.1153 |
| 6715 | SRD5A1 | P17T-E | Human | Esophagus | ESCC | 2.08e-10 | 6.32e-01 | 0.1278 |
| 6715 | SRD5A1 | P19T-E | Human | Esophagus | ESCC | 3.28e-02 | 4.93e-01 | 0.1662 |
| 6715 | SRD5A1 | P20T-E | Human | Esophagus | ESCC | 1.44e-54 | 1.36e+00 | 0.1124 |
| 6715 | SRD5A1 | P21T-E | Human | Esophagus | ESCC | 1.57e-13 | 4.17e-01 | 0.1617 |
| 6715 | SRD5A1 | P22T-E | Human | Esophagus | ESCC | 4.99e-11 | 2.52e-01 | 0.1236 |
| 6715 | SRD5A1 | P23T-E | Human | Esophagus | ESCC | 4.13e-18 | 6.28e-01 | 0.108 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00323559 | Oral cavity | OSCC | response to estradiol | 79/7305 | 141/18723 | 3.01e-05 | 2.76e-04 | 79 |
| GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
| GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
| GO:00466773 | Oral cavity | OSCC | response to antibiotic | 32/7305 | 47/18723 | 5.11e-05 | 4.27e-04 | 32 |
| GO:000762316 | Oral cavity | OSCC | circadian rhythm | 110/7305 | 210/18723 | 5.40e-05 | 4.48e-04 | 110 |
| GO:19016555 | Oral cavity | OSCC | cellular response to ketone | 56/7305 | 96/18723 | 9.61e-05 | 7.25e-04 | 56 |
| GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
| GO:003196018 | Oral cavity | OSCC | response to corticosteroid | 86/7305 | 167/18723 | 6.79e-04 | 3.79e-03 | 86 |
| GO:00335747 | Oral cavity | OSCC | response to testosterone | 27/7305 | 42/18723 | 8.00e-04 | 4.29e-03 | 27 |
| GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
| GO:005138418 | Oral cavity | OSCC | response to glucocorticoid | 76/7305 | 148/18723 | 1.49e-03 | 7.15e-03 | 76 |
| GO:00603484 | Oral cavity | OSCC | bone development | 99/7305 | 205/18723 | 4.13e-03 | 1.68e-02 | 99 |
| GO:00148233 | Oral cavity | OSCC | response to activity | 41/7305 | 76/18723 | 5.78e-03 | 2.22e-02 | 41 |
| GO:00067203 | Oral cavity | OSCC | isoprenoid metabolic process | 59/7305 | 116/18723 | 6.18e-03 | 2.33e-02 | 59 |
| GO:00082024 | Oral cavity | OSCC | steroid metabolic process | 146/7305 | 319/18723 | 7.78e-03 | 2.85e-02 | 146 |
| GO:00715486 | Oral cavity | OSCC | response to dexamethasone | 23/7305 | 39/18723 | 9.09e-03 | 3.26e-02 | 23 |
| GO:00219876 | Oral cavity | OSCC | cerebral cortex development | 57/7305 | 114/18723 | 1.09e-02 | 3.71e-02 | 57 |
| GO:00215435 | Oral cavity | OSCC | pallium development | 81/7305 | 169/18723 | 1.11e-02 | 3.76e-02 | 81 |
| GO:00713848 | Oral cavity | OSCC | cellular response to corticosteroid stimulus | 33/7305 | 61/18723 | 1.19e-02 | 4.02e-02 | 33 |
| GO:002290019 | Oral cavity | LP | electron transport chain | 108/4623 | 175/18723 | 2.21e-25 | 9.90e-23 | 108 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRD5A1 | SNV | Missense_Mutation | c.460N>C | p.Gly154Arg | p.G154R | P18405 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SRD5A1 | SNV | Missense_Mutation | c.688N>C | p.Ser230Pro | p.S230P | P18405 | protein_coding | tolerated(0.2) | benign(0.145) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SRD5A1 | SNV | Missense_Mutation | novel | c.408N>A | p.Ser136Arg | p.S136R | P18405 | protein_coding | deleterious(0.01) | possibly_damaging(0.463) | TCGA-AA-3869-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
| SRD5A1 | SNV | Missense_Mutation | c.353C>T | p.Thr118Ile | p.T118I | P18405 | protein_coding | tolerated(0.29) | benign(0) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
| SRD5A1 | SNV | Missense_Mutation | c.613N>A | p.Glu205Lys | p.E205K | P18405 | protein_coding | deleterious(0.02) | possibly_damaging(0.856) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SRD5A1 | SNV | Missense_Mutation | novel | c.721N>T | p.Leu241Phe | p.L241F | P18405 | protein_coding | deleterious(0.02) | probably_damaging(0.917) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SRD5A1 | SNV | Missense_Mutation | c.758N>G | p.Ile253Ser | p.I253S | P18405 | protein_coding | tolerated(0.22) | benign(0.065) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SRD5A1 | SNV | Missense_Mutation | rs374499334 | c.674N>T | p.Thr225Met | p.T225M | P18405 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SRD5A1 | SNV | Missense_Mutation | novel | c.759N>G | p.Ile253Met | p.I253M | P18405 | protein_coding | tolerated(0.06) | benign(0.222) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SRD5A1 | SNV | Missense_Mutation | novel | c.286G>T | p.Gly96Trp | p.G96W | P18405 | protein_coding | deleterious(0.03) | benign(0.014) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6715 | SRD5A1 | DRUGGABLE GENOME | LEVONORGESTREL | LEVONORGESTREL | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | DUTASTERIDE | DUTASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | BEXLOSTERIDE | BEXLOSTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | FR-146687 | |||
| 6715 | SRD5A1 | DRUGGABLE GENOME | FINASTERIDE | FINASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | LY-266111 | CHEMBL29166 | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | FINASTERIDE | FINASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | DUTASTERIDE | DUTASTERIDE | ||
| 6715 | SRD5A1 | DRUGGABLE GENOME | inhibitor | CHEMBL1200969 | DUTASTERIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |